$2.79
0.24[9.41%]
At close: Apr 19
$2.79
0[0.00%]
After Hours: 6:15PM EDT
BioXcel Therapeutics
(NASDAQ:BTAI)BioXcel Therapeutics Stock (NASDAQ:BTAI), Analyst Ratings, Price Targets, Predictions
BioXcel Therapeutics Inc has a consensus price target of $8.3, established from looking at the 50 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Canaccord Genuity, and B of A Securities on March 18, 2024, March 14, 2024, and March 13, 2024. With an average price target of $8.33 between HC Wainwright & Co., Canaccord Genuity, and B of A Securities, there's an implied 198.69% upside for BioXcel Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Canaccord Genuity
B of A Securities
UBS
Truist Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for BioXcel Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/18/2024 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 294.27% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 150.9% | Canaccord Genuity | Sumant Kulkarni | $18 → $7 | Maintains | Buy | Get Alert |
| 03/13/2024 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 150.9% | B of A Securities | Geoff Meacham | $8 → $7 | Maintains | Buy | Get Alert |
| 02/21/2024 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 43.37% | UBS | Colin Bristow | $9 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 11/15/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 294.27% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 294.27% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 10/26/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 294.27% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 10/05/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | — | Truist Securities | Robyn Karnauskas | — | Downgrade | Buy → Hold | Get Alert |
| 09/13/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 294.27% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 294.27% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 294.27% | HC Wainwright & Co. | Raghuram Selvaraju | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/23/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 43.37% | Mizuho | Graig Suvannavejh | → $4 | Reiterates | Neutral → Neutral | Get Alert |
| 08/18/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 294.27% | HC Wainwright & Co. | Raghuram Selvaraju | $60 → $11 | Maintains | Buy | Get Alert |
| 08/15/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 43.37% | Goldman Sachs | Corinne Jenkins | $12 → $4 | Maintains | Neutral | Get Alert |
| 08/15/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 43.37% | Mizuho | Graig Suvannavejh | $40 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 08/15/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 1011.11% | Truist Securities | Robyn Karnauskas | $71 → $31 | Maintains | Buy | Get Alert |
| 08/15/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 616.85% | Canaccord Genuity | Sumant Kulkarni | $76 → $20 | Maintains | Buy | Get Alert |
| 07/17/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | — | Guggenheim | Yatin Suneja | — | Downgrade | Buy → Neutral | Get Alert |
| 07/03/2023 | BTAI | Buy Now | BioXcel Therapeutics | $2.79 | 2050.54% | HC Wainwright & Co. | Raghuram Selvaraju | $66 → $60 | Maintains | Buy | Get Alert |
FAQ
What is the target price for BioXcel Therapeutics (BTAI)?
The latest price target for BioXcel Therapeutics (NASDAQ: BTAI) was reported by HC Wainwright & Co. on March 18, 2024. The analyst firm set a price target for $11.00 expecting BTAI to rise to within 12 months (a possible 294.27% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioXcel Therapeutics (BTAI)?
The latest analyst rating for BioXcel Therapeutics (NASDAQ: BTAI) was provided by HC Wainwright & Co., and BioXcel Therapeutics reiterated their buy rating.
When was the last upgrade for BioXcel Therapeutics (BTAI)?
The last upgrade for BioXcel Therapeutics Inc happened on December 1, 2022 when Goldman Sachs raised their price target to $16. Goldman Sachs previously had a sell for BioXcel Therapeutics Inc.
When was the last downgrade for BioXcel Therapeutics (BTAI)?
The last downgrade for BioXcel Therapeutics Inc happened on February 21, 2024 when UBS changed their price target from $9 to $4 for BioXcel Therapeutics Inc.
When is the next analyst rating going to be posted or updated for BioXcel Therapeutics (BTAI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioXcel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioXcel Therapeutics was filed on March 18, 2024 so you should expect the next rating to be made available sometime around March 18, 2025.
Is the Analyst Rating BioXcel Therapeutics (BTAI) correct?
While ratings are subjective and will change, the latest BioXcel Therapeutics (BTAI) rating was a reiterated with a price target of $0.00 to $11.00. The current price BioXcel Therapeutics (BTAI) is trading at is $2.79, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.